ONCY: Pelareorep pairs encouraging mCRC and SCAC data with a 2027 clinical development push
Moins d'1 minute de lecture
Pelareorep is being developed as a GI tumor immunotherapy platform, with reported mCRC and SCAC activity and planned studies targeting biomarker-defined colorectal cancer and later-line anal cancer. Development milestones extend into 2027.
Original document: Oncolytics Biotech Inc. [ONCY] Slides Release — Nov. 11 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr